These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15264458)

  • 21. Management of hyperuricemia and gout in CKD.
    Gaffo AL; Saag KG
    Am J Kidney Dis; 2008 Nov; 52(5):994-1009. PubMed ID: 18971014
    [No Abstract]   [Full Text] [Related]  

  • 22. [Hyperuricemia - more than gout : Impact on cardiovascular risk and renal insufficiency].
    Sellin L; Kielstein JT; de Groot K
    Z Rheumatol; 2015 May; 74(4):322-8. PubMed ID: 25962453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of Gout and Hyperuricemia in CKD.
    Vargas-Santos AB; Neogi T
    Am J Kidney Dis; 2017 Sep; 70(3):422-439. PubMed ID: 28456346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline.
    Shekelle PG; Newberry SJ; FitzGerald JD; Motala A; O'Hanlon CE; Tariq A; Okunogbe A; Han D; Shanman R
    Ann Intern Med; 2017 Jan; 166(1):37-51. PubMed ID: 27802478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperuricemia in adult renal allograft recipients: prevalence and predictors.
    Malheiro J; Almeida M; Fonseca I; Martins LS; Pedroso S; Dias L; Henriques AC; Cabrita A
    Transplant Proc; 2012 Oct; 44(8):2369-72. PubMed ID: 23026595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A literature review of the epidemiology and treatment of acute gout.
    Kim KY; Ralph Schumacher H; Hunsche E; Wertheimer AI; Kong SX
    Clin Ther; 2003 Jun; 25(6):1593-617. PubMed ID: 12860487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperuricemia and Acute Renal Failure in Renal Transplant Recipients Treated With High-Dose Mizoribine.
    Akioka K; Ishikawa T; Osaka M; Kadotani Y; Okugawa K; Nakano K; Osaka Y; Tsuchiya K; Sako H
    Transplant Proc; 2017; 49(1):73-77. PubMed ID: 28104163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gout: can management be improved?
    Schlesinger N; Schumacher HR
    Curr Opin Rheumatol; 2001 May; 13(3):240-4. PubMed ID: 11333356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on gout: new therapeutic strategies and options.
    Terkeltaub R
    Nat Rev Rheumatol; 2010 Jan; 6(1):30-8. PubMed ID: 20046204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic approaches in the treatment of gout.
    Pillinger MH; Mandell BF
    Semin Arthritis Rheum; 2020 Jun; 50(3S):S24-S30. PubMed ID: 32620199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Environmental Triggers of Hyperuricemia and Gout.
    Helget LN; Mikuls TR
    Rheum Dis Clin North Am; 2022 Nov; 48(4):891-906. PubMed ID: 36333002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 2011 Recommendations for the diagnosis and management of gout and hyperuricemia.
    Hamburger M; Baraf HS; Adamson TC; Basile J; Bass L; Cole B; Doghramji PP; Guadagnoli GA; Hamburger F; Harford R; Lieberman JA; Mandel DR; Mandelbrot DA; McClain BP; Mizuno E; Morton AH; Mount DB; Pope RS; Rosenthal KG; Setoodeh K; Skosey JL; Edwards NL;
    Postgrad Med; 2011 Nov; 123(6 Suppl 1):3-36. PubMed ID: 22156509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia.
    Shen X; Li J; Fu Q; Liu L; Gao X; Chen X; Chen P; Wang C
    J Clin Pharm Ther; 2019 Apr; 44(2):318-326. PubMed ID: 30582178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients.
    Sofue T; Inui M; Hara T; Nishijima Y; Moriwaki K; Hayashida Y; Ueda N; Nishiyama A; Kakehi Y; Kohno M
    Drug Des Devel Ther; 2014; 8():245-53. PubMed ID: 24600205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hyperuricemia and gout: diagnosis and therapy].
    Tausche AK; Unger S; Richter K; Wunderlich C; Grässler J; Roch B; Schröder HE
    Internist (Berl); 2006 May; 47(5):509-20; quiz 521. PubMed ID: 16586130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Austrian 3e-recommendations for diagnosis and management of gout 2013].
    Sautner J; Gruber J; Herold M; Zwerina J; Leeb BF
    Wien Klin Wochenschr; 2014 Feb; 126(3-4):79-89. PubMed ID: 24297266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gout: a review of its aetiology and treatment.
    Li EK
    Hong Kong Med J; 2004 Aug; 10(4):261-70. PubMed ID: 15299172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements.
    Li Q; Li X; Wang J; Liu H; Kwong JS; Chen H; Li L; Chung SC; Shah A; Chen Y; An Z; Sun X; Hemingway H; Tian H; Li S
    BMJ Open; 2019 Aug; 9(8):e026677. PubMed ID: 31446403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging strategies for treating gout.
    Huddleston EM; Gaffo AL
    Curr Opin Pharmacol; 2022 Aug; 65():102241. PubMed ID: 35609384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.